Browsing by Author "Kutlu, Yasin"
Now showing items 1-7 of 7
-
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gürbüz, Mustafa; Kutlu, Yasin; Akkuş, Erman; Köksoy, Elif Berna; Köse, Naziyet; Öven, Bala Başak; Oyan Uluç, Başak; Demiray, Atike Gökçen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Üskent, Necdet; Akbaş, Sinem; Selçukbiricik, Fatih; İnal, Ali; Bilici, Ahmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Ünal, Çağlar; Hizal, Mutlu; Şendur, Mehmet Ali Nahit; Korkmaz, Mustafa; Karadurmuş, Nuri; Ertürk, İsmail; Göksu, Sema Sezgin; Tatlı, Ali Murat; Güven, Deniz Can; Kılıçkap, Saadettin; Paksoy, Nail; Aydıner, Adnan; Yeşil Çınkır, Havva; Özkul, Özlem; Öztürk, Akın; Ballı, Sevinç; Kemal, Yasemin; Erdoğan, Atike Pınar; Er, Özlem; Yumuk, Perran Fulden; Demirkazık, Ahmet (Springer, 2022)Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In ... -
Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock
Toprak, İlkim Deniz; Eruzun, Hasan; Kutlu, Yasin; Arman, Yücel; Yumuştutan, Pembegül; Aydın Yoldemir, Şengül; Akarsu, Murat; Dikker, Okan; Tükek, Tufan (Ondokuz Mayis University, 2022)Nesfatin-1 is an anorectic protein, and we expect it to decrease during sepsis and septic shock. We aimed to analyze it and determine the relationship between Nesfatin-1 levels and quick Sequential Organ Failure Assessment(qSOFA) ... -
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
Kutlu, Yasin; Göktaş Aydın, Sabin; Bilici, Ahmet; Öven, Bala Başak; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Hamdard, Jamshid (NLM (Medline), 2023)Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Aydın, S. G.; Kutlu, Yasin; Açıkgöz, Özgür; Bilici, A.; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Elsevier Science Inc., 2021)Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Açıkgöz, Özgür; Kutlu, Yasin; Bilici, Ahmet; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Ankara Society of Hematology and Oncology, 2021)Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ... -
The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Ölmez, Ömer Fatih; Öven, Bala Başak; Açıkgöz, Özgür; Çakır, Tansel; Basım, Pelin; Çakır, Aslı; Kutlu, Yasin; Hamdard, Jamshid (Karger, 2022)Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy ...
